Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

ILF2 Regulates RNA splicing of DNA Damage Response Genes to confer poor prognosis in 1q21-Amplified Multiple Myeloma

ABSTRACT: This SuperSeries is composed of the SubSeries listed below.

ORGANISM(S): Homo sapiens

PROVIDER: GSE83665 | GEO | 2017/05/23

SECONDARY ACCESSION(S): PRJNA326671

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Similar Datasets

ILF2 Regulates RNA Splicing of DNA Damage Response Genes to Confer Poor Prognosis in 1q21-Amplified Multiple Myeloma

Project description:To understand whether ILF2 is required to ensure the alternative splicing and processing of specific pre-mRNAs in Multiple Myeloma (MM), both in physiological and DNA damage conditions, we performed RNA sequencing (RNA-Seq) analysis of untreated or melphalan-treated ILF2-depleted JJN3 cells. Non-silencing or ILF2 shRNA transduced JJN3 cells were treated with melphalan for 10 hours.

2017-01-01 | GSE83712 | GEO

ILF2 Is a Regulator of RNA Splicing and DNA Damage Response in 1q21-Amplified Multiple Myeloma.

Project description: Not available

| S-EPMC5593798 | biostudies-literature

ILF2 Regulates RNA splicing of DNA Damage Response Genes to confer poor prognosis in 1q21-Amplified Multiple Myeloma

Project description:ILF2 Regulates RNA splicing of DNA Damage Response Genes to confer poor prognosis in 1q21-Amplified Multiple Myeloma

| PRJNA326671 | ENA

Multiple myeloma immunoglobulin lambda translocations portend poor prognosis

Project description:Multiple myeloma is a malignancy of antibody-secreting plasma cells. Most patients benefit from current therapies, however, 20% of patients relapse or die within two years. To better understand and identify these ‘high-risk’ cases, we analyzed the translocation landscape of myeloma from 795 newly-diagnosed patients by whole genome sequencing from the CoMMpass study. Translocations involving the immunoglobulin lambda (IgL) locus were identified in 10% of patients, and were indicative of poor prognosis. Importantly, 70% of IgL translocations co-occurred with hyperdiploid disease, a marker of standard risk, potentially resulting in the misclassification of IgL-translocated myeloma. Most IgL-translocations coincided with focal amplifications that were centered on the 3’ enhancer. Patients with IgL-translocations failed to benefit from immunomodulatory imide drugs (IMiDs), which target the lymphocyte-specific transcription factor IKZF1 that is bound to the IgL 3’ enhancer at some of the highest levels in the myeloma epigenome. These data implicate IgL-translocation as a driver of poor prognosis which may be due in part to IMID resistance.

2019-03-13 | GSE121912 | GEO

Multiple myeloma immunoglobulin lambda translocations portend poor prognosis.

Project description: Not available

| S-EPMC6478743 | biostudies-literature

Splicing Factor SRSF1 Promotes Tumorigenesis via Oncogenic Splice-Switching and Predicts Poor Prognosis in Multiple Myeloma

Project description:Alternative splicing (AS) and its regulation play critical roles in cancer, yet the dysregulation of AS and its molecular bases in multiple myeloma (MM) development have not yet been elucidated. We identified SRSF1 as a key splicing factor in tumor progression, SRSF1 expression was frequently upregulated in MM and correlated with poor survival.We conducted transcriptome comparison of SRSF1-knockdown and control cells highlighted the functional importance of SRSF1 in mediating MM progression through regulating AS, and revealed the upstream and downstream molecular regulation mechanism of SRSF1. Further investigation to clarify molecular mechanisms and to replicate our findings is necessary. Thus, our findings are of high translational relevance and are expected to have a substantial impact on the development of a promising epigenetic approach for investigating targeted therapies for MM with high SRSF1 expression.

2022-09-04 | GSE160724 | GEO

High expression of CHML predicts poor prognosis of multiple myeloma.

Project description: Not available

| S-EPMC6856588 | biostudies-literature

Tetraploidy is associated with poor prognosis at diagnosis in multiple myeloma.

Project description: Not available

| S-EPMC8019381 | biostudies-literature

Multiple myeloma immunoglobulin lambda translocations portend poor prognosis

Project description:Multiple myeloma immunoglobulin lambda translocations portend poor prognosis

| PRJNA499054 | ENA

High expression of UBE2T predicts poor prognosis and survival in multiple myeloma.

Project description: Not available